Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Robrecht

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Leukemia|March 27, 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Eugen Tausch, Dan A Landau, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.
Hemasphere|May 1, 2026
Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscapeCosima Drewes, Cristina López, Juan Emilio Martinez-Manjón, et al.
Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.
Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Leukemia|March 27, 2019
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemiaBilly Michael Chelliah Jebaraj, Eugen Tausch, Dan A Landau, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.
Hemasphere|May 1, 2026
Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscapeCosima Drewes, Cristina López, Juan Emilio Martinez-Manjón, et al.
Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.
Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Pageof 6